XBiotech (XBIT) Income from Continuing Operations (2014 - 2026)
XBiotech (XBIT) posted quarterly Income from Continuing Operations of 26892000.0 for Q4 2025, down 155.92% year-over-year from 48090731.11 in Q4 2024, and down 347.6% quarter-over-quarter from 6008000.0 in Q3 2025.
XBiotech (XBIT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
XBiotech's Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 26892000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 155.92% year-over-year to 26892000.0; the TTM figure through Dec 2025 stood at 45540000.0 (down 18.19% YoY), while the FY2025 annual figure was 45540000.0, down 18.19% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 26892000.0, down from 6008000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1756000.0 in Q2 2025, with the low at 26892000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 5701500.0 (2022), against an average of 7883200.0.
- The sharpest annual moves came in 2021 and 2025: Income from Continuing Operations tumbled 18242.86% in 2021, then surged 86.5% in 2025.
- XBiotech's Income from Continuing Operations stood at 5056000.0 in 2021, then jumped by 36.65% to 3203000.0 in 2022, then plunged by 46.55% to 4694000.0 in 2023, then tumbled by 123.86% to 10508000.0 in 2024, then tumbled by 155.92% to 26892000.0 in 2025.
- Business Quant data shows XBIT's Income from Continuing Operations at 26892000.0 in Q4 2025, 6008000.0 in Q3 2025, and 1756000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | XBiotech | 69.51 Mn | 69.51 Mn | - | -6.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.73 Mn |
| Dec 31, 2025 | -26.89 Mn |
| Sep 30, 2025 | -6.01 Mn |
| Jun 30, 2025 | -1.76 Mn |
| Mar 31, 2025 | -10.88 Mn |
| Dec 31, 2024 | -10.51 Mn |
| Sep 30, 2024 | -5.02 Mn |
| Jun 30, 2024 | -13.01 Mn |
| Mar 31, 2024 | -10.00 Mn |
| Dec 31, 2023 | -4.69 Mn |
| Sep 30, 2023 | -7.36 Mn |
| Jun 30, 2023 | -8.74 Mn |
| Mar 31, 2023 | -3.89 Mn |
| Dec 31, 2022 | -3.20 Mn |
| Sep 30, 2022 | -12.66 Mn |
| Jun 30, 2022 | -11.64 Mn |
| Mar 31, 2022 | -5.40 Mn |
| Dec 31, 2021 | -5.06 Mn |
| Sep 30, 2021 | -3.26 Mn |
| Jun 30, 2021 | -5.12 Mn |